文献速递外周动脉疾病

冠心病患者踝臂指数筛查以优化药物治疗的成本效益分析

Cost-effectiveness analysis of ankle-brachial index screening in patients with coronary artery disease to optimize medical management.
PubMed 文献 · J Vasc Surg · 2021-06-25

本研究采用马尔可夫模型评估冠心病患者通过踝臂指数筛查外周动脉疾病并据此处方低剂量利伐沙班的成本效益。模型假设所有筛查患者均适合低剂量利伐沙班,筛查成本为每人100美元,医生访视100美元,利伐沙班每月470美元,周期30天,分析35年。结果显示筛查组决策成本94,953美元,非筛查组82,553美元,筛查获得0.060个质量调整生命年,增量成本效益比为每质量调整生命年207,491美元,结论认为当前策略不具有成本效益。

要点

  • 冠心病患者ABI筛查以启动低剂量利伐沙班,ICER为每QALY 207,491美元,未达成本效益阈值。
  • 利伐沙班费用降至每月95美元以下时,筛查策略在每QALY 50,000美元支付意愿阈值下具有成本效益。
  • 对ICER影响最大的因素为利伐沙班相关的全因死亡率降低幅度和利伐沙班的高昂费用。

核心结论

  • 根据本模型,冠心病患者通过ABI筛查外周动脉疾病以启动低剂量利伐沙班,因全因死亡率降低不足和药物费用高昂,当前不具有成本效益。

研究设计与样本

  • 采用马尔可夫模型评估冠心病患者ABI筛查的成本效益,假设所有筛查患者均适合低剂量利伐沙班。
  • ABI筛查成本为每人100美元,医生访视费用100美元,利伐沙班费用每月470美元,周期30天,分析时间跨度35年。
  • 效果指标为质量调整生命年,基于既往研究,计算增量成本效益比,并进行确定性和概率敏感性分析。

主要发现

  • 筛查组决策成本为94,953美元,非筛查组为82,553美元。
  • 筛查获得0.060个质量调整生命年,增量成本效益比为每质量调整生命年207,491美元。
  • 对ICER影响最大的变量为利伐沙班相关的全因死亡率降低幅度和利伐沙班的高昂费用。
  • 若利伐沙班费用低于每月95美元,在每质量调整生命年50,000美元支付意愿阈值下筛查具有成本效益。

关键数值与推荐

  • ABI筛查成本每人100美元,医生访视费用100美元,利伐沙班费用每月470美元。
  • 筛查组成本94,953美元,非筛查组成本82,553美元,QALY增益0.060,ICER为每QALY 207,491美元。
  • 利伐沙班费用低于每月95美元时,在每QALY 50,000美元支付意愿阈值下具有成本效益。

临床怎么用

  • 当前背景下,冠心病患者常规ABI筛查以启动低剂量利伐沙班不具有成本效益。
  • 血管外科医生可在外周动脉疾病患者中处方或倡导低剂量利伐沙班以改善心血管结局。

局限性

  • 模型假设所有筛查患者均适合低剂量利伐沙班,可能高估筛查获益。
  • QALYs来自既往研究,成本参数基于特定假设,可能影响结果外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Screening for peripheral artery disease (PAD) with the ankle-brachial index (ABI) test is currently not recommended in the general population; however, previous studies advocate screening in high-risk populations. Although providers may be hesitant to prescribe low-dose rivaroxaban to patients with coronary artery disease (CAD) alone, given the reduction in cardiovascular events and death associated with rivaroxaban, screening for PAD with the ABI test and accordingly prescribing rivaroxaban may provide additional benefits. We sought to describe the cost-effectiveness of screening for PAD in patients with CAD to optimize this high-risk populations' medical management. METHODS: We used a Markov model to evaluate the ABI test in patients with CAD. We assumed that all patients screened would be candidates for low-dose rivaroxaban. We assessed the cost of ABI screening at $100 per patient and added additional charges for physician visits ($100) and rivaroxaban cost ($470 per month). We used a 30-day cycle and performed analysis over 35 years. We evaluated quality-adjusted life years (QALYs) from previous studies and determined the incremental cost-effectiveness ratio (ICER) according to our model. We performed a deterministic and probabilistic sensitivity analyses of variables with uncertainty and reported them in a Tornado diagram showing the variables with the greatest effect on the ICER. RESULTS: Our model estimates decision costs to screen or not screen at $94,953 and $82,553, respectively. The QALYs gained from screening was 0.060, generating an ICER of $207,491 per QALY. Factors most influential on the ICER were the reduction in all-cause mortality associated with rivaroxaban and the prohibitively high cost of rivaroxaban. If rivaroxaban cost less than $95 per month, this would make screening cost-effective based on a willingness to pay threshold of $50,000 per QALY. CONCLUSIONS: According to our model, screening patients with CAD for PAD to start low-dose rivaroxaban is not currently cost-effective due to insufficient reduction in all-cause mortality and high medication costs. Nevertheless, vascular surgeons have a unique opportunity to prescribe or advocate for low-dose rivaroxaban in patients with PAD to improve cardiovascular outcomes.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Minami HR, Itoga NK, George EL, et al. Cost-effectiveness analysis of ankle-brachial index screening in patients with coronary artery disease to optimize medical management. J Vasc Surg. 2021. PMID: 34175383. doi:10.1016/j.jvs.2021.05.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。